312 related articles for article (PubMed ID: 21885031)
1. [Rheumatoid arthritis: a cardiovascular disease?].
Daïen CI; Fesler P
Ann Cardiol Angeiol (Paris); 2012 Apr; 61(2):111-7. PubMed ID: 21885031
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis.
Solomon DH; Avorn J; Katz JN; Weinblatt ME; Setoguchi S; Levin R; Schneeweiss S
Arthritis Rheum; 2006 Dec; 54(12):3790-8. PubMed ID: 17136752
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular risk in rheumatoid arthritis.
Nurmohamed MT
Autoimmun Rev; 2009 Jul; 8(8):663-7. PubMed ID: 19393192
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications.
Pieringer H; Pichler M
QJM; 2011 Jan; 104(1):13-26. PubMed ID: 21068083
[TBL] [Abstract][Full Text] [Related]
5. What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology.
Dixon WG; Symmons DP
Ann Rheum Dis; 2007 Sep; 66(9):1132-6. PubMed ID: 17251223
[TBL] [Abstract][Full Text] [Related]
6. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
Roubille C; Richer V; Starnino T; McCourt C; McFarlane A; Fleming P; Siu S; Kraft J; Lynde C; Pope J; Gulliver W; Keeling S; Dutz J; Bessette L; Bissonnette R; Haraoui B
Ann Rheum Dis; 2015 Mar; 74(3):480-9. PubMed ID: 25561362
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs.
Avouac J; Allanore Y
Expert Opin Pharmacother; 2008 May; 9(7):1121-8. PubMed ID: 18422470
[TBL] [Abstract][Full Text] [Related]
8. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?
Gonzalez A; Maradit Kremers H; Crowson CS; Ballman KV; Roger VL; Jacobsen SJ; O'Fallon WM; Gabriel SE
Ann Rheum Dis; 2008 Jan; 67(1):64-9. PubMed ID: 17517756
[TBL] [Abstract][Full Text] [Related]
9. Effects of TNFα inhibitors on adiposity and other cardiovascular risk factors: implications for the cardiovascular prognosis in patients with rheumatoid arthritis.
Toussirot É
Expert Opin Drug Saf; 2015 Apr; 14(4):525-32. PubMed ID: 25599626
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular disease in rheumatoid arthritis: disease and treatment interactions and their implications on treatment decisions.
Sanders S; Geraci SA
J Miss State Med Assoc; 2010 Mar; 51(3):75-80. PubMed ID: 20827876
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for cardiovascular disease in rheumatoid arthritis.
Gabriel SE; Crowson CS
Curr Opin Rheumatol; 2012 Mar; 24(2):171-6. PubMed ID: 22249350
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risk in rheumatoid arthritis: how to lower the risk?
van Breukelen-van der Stoep DF; Klop B; van Zeben D; Hazes JM; Castro Cabezas M
Atherosclerosis; 2013 Nov; 231(1):163-72. PubMed ID: 24125429
[TBL] [Abstract][Full Text] [Related]
13. Disease activity in rheumatoid arthritis and the risk of cardiovascular events.
Solomon DH; Reed GW; Kremer JM; Curtis JR; Farkouh ME; Harrold LR; Hochberg MC; Tsao P; Greenberg JD
Arthritis Rheumatol; 2015 Jun; 67(6):1449-55. PubMed ID: 25776112
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory arthritis as a novel risk factor for cardiovascular disease.
John H; Kitas G
Eur J Intern Med; 2012 Oct; 23(7):575-9. PubMed ID: 22841864
[TBL] [Abstract][Full Text] [Related]
15. Do statins reduce the cardiovascular risk in patients with rheumatoid arthritis?
Danninger K; Hoppe UC; Pieringer H
Int J Rheum Dis; 2014 Jul; 17(6):606-11. PubMed ID: 24931356
[TBL] [Abstract][Full Text] [Related]
16. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists.
Carmona L; Descalzo MA; Perez-Pampin E; Ruiz-Montesinos D; Erra A; Cobo T; Gómez-Reino JJ;
Ann Rheum Dis; 2007 Jul; 66(7):880-5. PubMed ID: 17324968
[TBL] [Abstract][Full Text] [Related]
17. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.
Wolfe F; Caplan L; Michaud K
Arthritis Rheum; 2006 Feb; 54(2):628-34. PubMed ID: 16447241
[TBL] [Abstract][Full Text] [Related]
18. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
Wolfe F; Michaud K
Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
[TBL] [Abstract][Full Text] [Related]
19. Therapy Insight: managing cardiovascular risk in patients with rheumatoid arthritis.
Giles JT; Post W; Blumenthal RS; Bathon JM
Nat Clin Pract Rheumatol; 2006 Jun; 2(6):320-9. PubMed ID: 16932711
[TBL] [Abstract][Full Text] [Related]
20. Appropriate and effective management of rheumatoid arthritis.
Breedveld FC; Kalden JR
Ann Rheum Dis; 2004 Jun; 63(6):627-33. PubMed ID: 15140767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
